Search

Your search keyword '"Beverloo, Berna H"' showing total 18 results
Start Over Author "Beverloo, Berna H"
18 results on '"Beverloo, Berna H"'

1. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921

Author

Apotheek O&O&O, Cancer, Brivio, Erica, Pennesi, Edoardo, Willemse, Marieke E, Huitema, Alwin D R, Jiang, Yilin, van Tinteren, Harm D R, van der Velden, Vincent H J, Beverloo, Berna H, den Boer, Monique L, Rammeloo, Lukas A J, Hudson, Chad, Heerema, Nyla, Kowalski, Karey, Zhao, Huadong, Kuttschreuter, Luke, Bautista Sirvent, Francisco J, Bukowinski, Andrew, Rizzari, Carmelo, Pollard, Jessica, Murillo-Sanjuán, Laura, Kutny, Matthew, Zarnegar-Lumley, Sara, Redell, Michele, Cooper, Stacy, Bertrand, Yves, Petit, Arnaud, Krystal, Julie, Metzler, Markus, Lancaster, Donna, Bourquin, Jean-Pierre, Motwani, Jayashree, van der Sluis, Inge M, Locatelli, Franco, Roth, Michael E, Hijiya, Nobuko, Zwaan, Christian M, Apotheek O&O&O, Cancer, Brivio, Erica, Pennesi, Edoardo, Willemse, Marieke E, Huitema, Alwin D R, Jiang, Yilin, van Tinteren, Harm D R, van der Velden, Vincent H J, Beverloo, Berna H, den Boer, Monique L, Rammeloo, Lukas A J, Hudson, Chad, Heerema, Nyla, Kowalski, Karey, Zhao, Huadong, Kuttschreuter, Luke, Bautista Sirvent, Francisco J, Bukowinski, Andrew, Rizzari, Carmelo, Pollard, Jessica, Murillo-Sanjuán, Laura, Kutny, Matthew, Zarnegar-Lumley, Sara, Redell, Michele, Cooper, Stacy, Bertrand, Yves, Petit, Arnaud, Krystal, Julie, Metzler, Markus, Lancaster, Donna, Bourquin, Jean-Pierre, Motwani, Jayashree, van der Sluis, Inge M, Locatelli, Franco, Roth, Michael E, Hijiya, Nobuko, and Zwaan, Christian M

Published
2024

2. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia:Results From the Phase I Part of Study ITCC054/COG AAML1921

Author

Brivio, Erica, Pennesi, Edoardo, Willemse, Marieke E., Huitema, Alwin D.R., Jiang, Yilin, Van Tinteren, Harm D.R., Van Der Velden, Vincent H.J., Beverloo, Berna H., Den Boer, Monique L., Rammeloo, Lukas A.J., Hudson, Chad, Heerema, Nyla, Kowalski, Karey, Zhao, Huadong, Kuttschreuter, Luke, Bautista Sirvent, Francisco J., Bukowinski, Andrew, Rizzari, Carmelo, Pollard, Jessica, Murillo-Sanjuán, Laura, Kutny, Matthew, Zarnegar-Lumley, Sara, Redell, Michele, Cooper, Stacy, Bertrand, Yves, Petit, Arnaud, Krystal, Julie, Metzler, Markus, Lancaster, Donna, Bourquin, Jean Pierre, Motwani, Jayashree, Van Der Sluis, Inge M., Locatelli, Franco, Roth, Michael E., Hijiya, Nobuko, Zwaan, Christian M., Brivio, Erica, Pennesi, Edoardo, Willemse, Marieke E., Huitema, Alwin D.R., Jiang, Yilin, Van Tinteren, Harm D.R., Van Der Velden, Vincent H.J., Beverloo, Berna H., Den Boer, Monique L., Rammeloo, Lukas A.J., Hudson, Chad, Heerema, Nyla, Kowalski, Karey, Zhao, Huadong, Kuttschreuter, Luke, Bautista Sirvent, Francisco J., Bukowinski, Andrew, Rizzari, Carmelo, Pollard, Jessica, Murillo-Sanjuán, Laura, Kutny, Matthew, Zarnegar-Lumley, Sara, Redell, Michele, Cooper, Stacy, Bertrand, Yves, Petit, Arnaud, Krystal, Julie, Metzler, Markus, Lancaster, Donna, Bourquin, Jean Pierre, Motwani, Jayashree, Van Der Sluis, Inge M., Locatelli, Franco, Roth, Michael E., Hijiya, Nobuko, and Zwaan, Christian M.

Abstract

PURPOSE Bosutinib is approved for adults with chronic myeloid leukemia (CML): 400 mg once daily in newly diagnosed (ND); 500 mg once daily in resistant/intolerant (R/I) patients. Bosutinib has a different tolerability profile than other tyrosine kinase inhibitors (TKIs) and potentially less impact on growth (preclinical data). The primary objective of this first-in-child trial was to determine the recommended phase II dose (RP2D) for pediatric R/I and ND patients. PATIENTS AND METHODS In the phase I part of this international, open-label trial (ClinicalTrials.gov identifier: NCT04258943), children age 1-18 years with R/I (per European LeukemiaNet 2013) Ph+ CML were enrolled using a 6 + 4 design, testing 300, 350, and 400 mg/m2 once daily with food. The RP2D was the dose resulting in 0/6 or 1/10 dose-limiting toxicities (DLTs) during the first cycle and achieving adult target AUC levels for the respective indication. As ND participants were only enrolled in phase II, the ND RP2D was selected based on data from R/I patients. Results Thirty patients were enrolled; 27 were evaluable for DLT: six at 300 mg/m2, 11 at 350 mg/m2 (one DLT), and 10 at 400 mg/m2 (one DLT). The mean AUCs at 300 mg/m2, 350 mg/m2, and 400 mg/m2 were 2.20 g h/mL, 2.52 g h/mL, and 2.66 g h/mL, respectively. The most common adverse event was diarrhea (93%; ≥grade 3: 11%). Seven patients stopped because of intolerance and eight because of insufficient response. Complete cytogenetic and major molecular response to bosutinib appeared comparable with other published phase I/II trials with second-generation TKIs in children. CONCLUSION Bosutinib was safe and effective. The pediatric RP2D was 400 mg/m2 once daily (max 600 mg/d) with food in R/I patients and 300 mg/m2 once daily (max 500 mg/d) with food in ND patients, which achieved targeted exposures as per adult experience.

Published
2024

4. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921.

Author

Brivio, Erica, Pennesi, Edoardo, Willemse, Marieke E., Huitema, Alwin D.R., Jiang, Yilin, van Tinteren, Harm D.R., van der Velden, Vincent H.J., Beverloo, Berna H., den Boer, Monique L., Rammeloo, Lukas A.J., Hudson, Chad, Heerema, Nyla, Kowalski, Karey, Zhao, Huadong, Kuttschreuter, Luke, Bautista Sirvent, Francisco J., Bukowinski, Andrew, Rizzari, Carmelo, Pollard, Jessica, and Murillo-Sanjuán, Laura

Published
2024
Full Text
View/download PDF

5. Megalobastic anemia, infantile leukemia, and immunodeficiency caused by a novel homozygous mutation in the DHFR gene

Author

Kuijpers, Taco W., primary, de Vries, Andrica C. H., additional, van Leeuwen, Ester M., additional, Ermens, A.(Ton) A. M., additional, de Pont, Saskia, additional, Smith, Desirée E. C., additional, Wamelink, Mirjam M. C., additional, Mensenkamp, Arjen R., additional, Nelen, Marcel R., additional, Lango Allen, Hana, additional, Pals, Steven T., additional, Beverloo, Berna H. B., additional, Huidekoper, Hidde H., additional, and Wagner, Anja, additional

Published
2022
Full Text
View/download PDF

6. Poster: AML-279 Molecularly-Defined De Novo and Secondary Acute Myeloid Leukemia Are Biologically and Clinically Different Entities

Author

Boertjes, Emma, primary, Hinai, Adil Al, additional, Stoetman, Elodie, additional, Compagne, Kyra G., additional, Grob, Tim, additional, Kavelaars, Francois G., additional, Rijken, Melissa, additional, Sanders, Mathijs, additional, Beverloo, Berna H., additional, Löwenberg, Bob, additional, and Valk, Peter J.M., additional

Published
2022
Full Text
View/download PDF

8. Association of unbalanced translocation der(1;7) with germline GATA2 mutations

Author

Kozyra, Emilia J, Göhring, Gudrun, Hickstein, Dennis D, Calvo, Katherine R, DiNardo, Courtney D, Dworzak, Michael, de Haas, Valerie, Starý, Jan, Hasle, Henrik, Shimamura, Akiko, Fleming, Mark D, Inaba, Hiroto, Lewis, Sara, Hsu, Amy P, Holland, Steven M, Arnold, Danielle E, Mecucci, Cristina, Keel, Siobán B, Bertuch, Alison A, Tawana, Kiran, Barzilai, Shlomit, Hirabayashi, Shinsuke, Onozawa, Masahiro, Lei, Shaohua, Alaiz, Helena, Andrikovics, Hajnalka, Betts, David, Beverloo, Berna H, Buechner, Jochen, Čermák, Martin, et al, Tchinda, Joelle, and University of Zurich

Subjects
1307 Cell Biology, 2403 Immunology, 1303 Biochemistry, 10036 Medical Clinic, 2720 Hematology, 610 Medicine & health
Published
2021
Full Text
View/download PDF

9. Association of unbalanced translocation der(1;7) with germline GATA2 mutations

Author

Kozyra, Emilia J., Göhring, Gudrun, Hickstein, Dennis D., Calvo, Katherine R., DiNardo, Courtney D., Dworzak, Michael, de Haas, Valerie, Starý, Jan, Hasle, Henrik, Shimamura, Akiko, Fleming, Mark D., Inaba, Hiroto, Lewis, Sara, Hsu, Amy P., Holland, Steven M., Arnold, Danielle E., Mecucci, Cristina, Keel, Siobán B., Bertuch, Alison A., Tawana, Kiran, Barzilai, Shlomit, Hirabayashi, Shinsuke, Onozawa, Masahiro, Lei, Shaohua, Alaiz, Helena, Andrikovics, Hajnalka, Betts, David, Beverloo, Berna H., Buechner, Jochen, Čermák, Martin, Cervera, José, Haus, Olga, Jahnukainen, Kirsi, Manola, Kalliopi N., Nebral, Karin, Pasquali, Francesco, Tchinda, Joelle, Turkiewicz, Dominik, Van Roy, Nadine, Zemanova, Zuzana, Pastor, Victor B., Strahm, Brigitte, Noellke, Peter, Niemeyer, Charlotte M., Schlegelberger, Brigitte, Yoshimi, Ayami, and Wlodarski, Marcin W.

Published
2021
Full Text
View/download PDF

14. Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA

Author

Kluzek, Katarzyna, primary, Srebniak, Malgorzata I., additional, Majer, Weronika, additional, Ida, Agnieszka, additional, Milecki, Tomasz, additional, Huminska, Kinga, additional, van der Helm, Robert M., additional, Silesian, Adrian, additional, Wrzesinski, Tomasz M., additional, Wojciechowicz, Jacek, additional, Beverloo, Berna H., additional, Kwias, Zbigniew, additional, Bluyssen, Hans A.R., additional, and Wesoly, Joanna, additional

Published
2017
Full Text
View/download PDF

15. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer

Author

Ling, Hui, primary, Spizzo, Riccardo, additional, Atlasi, Yaser, additional, Nicoloso, Milena, additional, Shimizu, Masayoshi, additional, Redis, Roxana S., additional, Nishida, Naohiro, additional, Gafà, Roberta, additional, Song, Jian, additional, Guo, Zhiyi, additional, Ivan, Cristina, additional, Barbarotto, Elisa, additional, De Vries, Ingrid, additional, Zhang, Xinna, additional, Ferracin, Manuela, additional, Churchman, Mike, additional, van Galen, Janneke F., additional, Beverloo, Berna H., additional, Shariati, Maryam, additional, Haderk, Franziska, additional, Estecio, Marcos R., additional, Garcia-Manero, Guillermo, additional, Patijn, Gijs A., additional, Gotley, David C., additional, Bhardwaj, Vikas, additional, Shureiqi, Imad, additional, Sen, Subrata, additional, Multani, Asha S., additional, Welsh, James, additional, Yamamoto, Ken, additional, Taniguchi, Itsuki, additional, Song, Min-Ae, additional, Gallinger, Steven, additional, Casey, Graham, additional, Thibodeau, Stephen N., additional, Le Marchand, Loïc, additional, Tiirikainen, Maarit, additional, Mani, Sendurai A., additional, Zhang, Wei, additional, Davuluri, Ramana V., additional, Mimori, Koshi, additional, Mori, Masaki, additional, Sieuwerts, Anieta M., additional, Martens, John W.M., additional, Tomlinson, Ian, additional, Negrini, Massimo, additional, Berindan-Neagoe, Ioana, additional, Foekens, John A., additional, Hamilton, Stanley R., additional, Lanza, Giovanni, additional, Kopetz, Scott, additional, Fodde, Riccardo, additional, and Calin, George A., additional

Published
2013
Full Text
View/download PDF

17. Mistaken Identity of Widely Used Esophageal Adenocarcinoma Cell Line TE-7

Author

Boonstra, Jurjen J., primary, van der Velden, Albertina W., additional, Beerens, Erwin C.W., additional, van Marion, Ronald, additional, Morita-Fujimura, Yuiko, additional, Matsui, Yasuhisa, additional, Nishihira, Tetsuro, additional, Tselepis, Chris, additional, Hainaut, Pierre, additional, Lowe, Anson W., additional, Beverloo, Berna H., additional, van Dekken, Herman, additional, Tilanus, Hugo W., additional, and Dinjens, Winand N.M., additional

Published
2007
Full Text
View/download PDF

18. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer.

Author

Hui Ling, Spizzo, Riccardo, Atlasi, Yaser, Nicoloso, Milena, Shimizu, Masayoshi, Redis, Roxana S., Nishida, Naohiro, Gaf, Roberta, Jian Song, Zhiyi Guo, Ivan, Cristina, Barbarotto, Elisa, De Vries, Ingrid, Xinna Zhang, Ferracin, Manuela, Churchman, Mike, van Galen, Janneke F., Beverloo, Berna H., Shariati, Maryam, and Haderk, Franziska

Subjects
*GENOTYPE-environment interaction, *CANCER invasiveness, *TUMOR growth, *RNA, *NUCLEIC acids
Abstract

The functional roles of SNPs within the 8q24 gene desert in the cancer phenotype are not yet well understood. Here, we report that CCAT2, a novel long non-coding RNA transcript (lncRNA) encompassing the rs6983267 SNP, is highly overexpressed in microsatellite-stable colorectal cancer and promotes tumor growth, metastasis and chromosomal instability. We demonstrate that MYC, miR-17-5p, and miR-20a are up-regulated by CCAT2 through TCF7L2-mediated transcriptional regulation. We further identify the physical interaction between CCAT2 and TCF7L2 resulting in an enhancement of WNT signaling activity. We show that CCAT2 is itself a WNT downstream target, which suggests the existence of a feedback loop. Finally, we demonstrated that the SNP status affects CCAT2 expression and the risk allele G produces more CCAT2 transcript. Our results support a new mechanism of MYC and WNT regulation by the novel lncRNA CCAT2 in colorectal cancer pathogenesis, and provide an alternative explanation on the SNP-conferred cancer risk. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results